早期小细胞肺癌手术治疗的实践差异及其对生存的影响
该研究基于2004至2013年美国国家癌症数据库,分析317家医院中5079例T1/T2 N0小细胞肺癌患者,发现各医院手术切除率差异巨大(最高四分位医院44.8% vs 最低7.6%),且高手术倾向医院的患者中位生存显著更长(25.3 vs 18.8个月)。
要点
- 早期小细胞肺癌手术实践在美国医院间存在巨大差异。
- 高手术倾向医院的患者接受切除的可能性是最低四分位医院的16.7倍。
核心结论
- 美国早期小细胞肺癌的手术治疗使用存在巨大差异,可能代表重要的质量改进机会。
研究设计与样本
- 回顾性队列研究,利用美国国家癌症数据库2004至2013年数据,纳入317家医院的5079例T1/T2 N0小细胞肺癌患者。
- 采用风险校正和可靠性校正的分层逻辑回归估计各医院调整后的切除比值比,并按手术使用率的观察值与预期值四分位数分组。
- 使用Kaplan-Meier曲线和Cox比例风险模型比较不同医院手术倾向下的患者生存。
主要发现
- 5079例患者中1260例接受了手术切除。
- 最高四分位医院患者接受手术切除的比例为44.8%,最低四分位为7.6%,调整后比值比为16.7(95%CI 12.59-22.18)。
- 最高四分位医院更多为学术中心(48% vs 21%),更多行肺叶切除术(28.3% vs 5.0%),治疗更多混合组织学肿瘤(11.1% vs 4.5%)。
- 最高四分位医院患者中位生存为25.3个月,最低四分位为18.8个月(p<0.0001)。
- 多因素Cox模型显示最高四分位医院患者死亡风险比为0.80(95%CI 0.72-0.89,p<0.0001)。
关键数值与推荐
- T1/T2 N0小细胞肺癌患者在纵隔分期阴性后推荐行肺叶切除术。
- 医院手术使用率最高四分位与最低四分位相比,调整后手术切除比值比为16.7(95%CI 12.59-22.18)。
- 最高四分位医院患者死亡风险比为0.80(95%CI 0.72-0.89,p<0.0001)。
临床怎么用
- 对于纵隔分期阴性的T1/T2 N0小细胞肺癌患者,应评估手术切除的可行性,并考虑在手术倾向较高的医院进行治疗。
- 医院层面应关注早期小细胞肺癌手术治疗的实践差异,作为质量改进的潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgical resection with lobectomy is recommended for T1/T2 N0 small cell lung cancer (SCLC) patients after negative mediastinal staging. We sought to characterize variation in surgical therapy for early SCLC and determine the effect of a hospital's practice patterns on patient survival. METHODS: The National Cancer Database was examined from 2004 to 2013. Risk- and reliability-adjusted hierarchical logistic regression was used to estimate the adjusted odds of resection by hospital. Hospitals were then grouped into quartiles by observed-to-expected rates of surgical treatment. Patient, tumor, and hospital characteristics were compared across quartiles. Kaplan-Meier plots and Cox proportional hazard models were built to compare patient survival as a function of a hospital's tendency to use surgical intervention. RESULTS: We identified 5,079 patients with T1/T2 N0 SCLC in 317 hospitals, and 1,260 underwent resection. Analysis after adjusting for demographic, comorbidity, and tumor factors showed patients treated at hospitals in the highest quartile of surgical use were 17 times more likely to undergo surgical resection than those in the lowest quartile (44.8% vs 7.6%; odds ratio, 16.7l; 95% confidence interval, 12.59 to 22.18). Hospitals in the highest quartile were more likely to be academic centers (48% vs 21%), more likely to perform lobectomy (28.3% vs 5.0%), and treated more mixed-histology tumors (11.1% vs 4.5%). Survival was significantly longer for patients treated at hospitals most likely to use surgical therapy (median, 25.3 vs. 18.8 months; p < 0.0001). Hazard ratio differences in mortality persisted in multivariate Cox models (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.89; p < 0.0001). CONCLUSIONS: Large variation exists in the use of surgical therapy for early SCLC in the United States, which may represent a significant quality improvement opportunity for patients with early SCLC.
引用
- Wakeam E, Byrne JP, Darling GE, et al. Surgical Treatment for Early Small Cell Lung Cancer: Variability in Practice and Impact on Survival. Ann Thorac Surg. 2017. PMID: 29106886. doi:10.1016/j.athoracsur.2017.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。